Dissolution profile evaluation of ciprofloxacin 250 mg tablets marketed as similar drugs in Brazil

Abstract

The present study has assessed, in vitro, eight pharmaceutical brands containing ciprofloxacin (250 mg). The product C is the reference drug (Cipro® - Bayer® S/A) and A, B, D, E, F, G and H are similar drugs. The following physicochemical tests have been carried out: dissolution test and dissolution profile, from which dissolution efficiency (DE) have been calculate. The maximum price for consumer has also been obtained, in order that it was possible to compare it with the performance of the products. The results show that all the produts comply with USP specifications, but only the products, B, C, E and H have been approved on the first stage (S1). After statistic treatment, by applying ANOVA and Tukey test for DE values, it has been noted that the products A and B, B and C, B and E, and C and H are similar, concerning to ciprofloxacin release in vitro. The products which demonstrated better performance are not same that are offered to the consumer as a better price option.